Clinical trial NCT00722098: Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients
Official title: Melanoma Peptide-Loaded Dendritic Cell Vaccine in HLA-A*0201 Patients With Stage IV Melanoma: A Phase II Randomized Trial to Compare Vaccination With and Without Cyclophosphamide Treatment.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Malignant Melanoma Stage IV
Keywords: Melanoma
Dendritic Cell
Vaccine
Immunotherapy
Cyclophosphamide
Lead sponsor: Baylor Research Institute
Sponsor class: OTHER
First posted: 2008-07-25
Enrollment: 9
Sex: ALL
Minimum age (years): 21
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether the combination of chemotherapy (Cyclophosphamide) and CD34-DC vaccines results in the improved rate of clinical responses for stage IV melanoma patients.

Detailed description: Vaccination of patients with metastatic melanoma using ex vivo generated dendritic cells (DCs) loaded with tumor-associated antigen(s) have been shown to induce tumor-specific immunity against melanoma antigens measured by in vitro assays and, in some cases, tumor regression. At the present time, the numbers of recorded patients with metastatic melanoma who have been treated with DC vaccinations are too small to predict with certainty the future of overall therapeutic value of DC vaccinations in the management of patients with metastatic melanoma. The purpose of this study is to gather data on feasibility and efficacy of novel combination therapy of CPA and a DC vaccine outlined in this protocol to treat metastatic melanoma.

Eligibility criteria: Inclusion Criteria:

1. Biopsy-proven metastatic melanoma, Stages M1a, M1b, M1c
2. HLA-A\*0201 phenotype
3. Age: 21-75 years
4. ECOG performance status 0-1
5. Measurable metastatic melanoma lesions by physical examination or radiographs or scans.
6. Adequate marrow function:

   * White count ≥ 4,000/microliter: Subjects who have recently completed chemotherapy will be allowed study entry with White count ≥ 3,500/microliter
   * Hemoglobin ≥ 10.0 gm: Subjects who have recently completed chemotherapy will be allowed study entry with Hemoglobin ≥ 9.0 gm.
   * Platelets ≥ 100,000/microliter
7. Adequate hepatic function:

   * Bilirubin ≤ 1.5/mg/dL
   * Alkaline phosphatase ≤ 5 times the upper limit of normal
   * SGOT ≤ 5 times the upper limit of normal
   * SGPT ≤ 5 times the upper limit of normal
8. Adequate renal function:

   * Serum creatinine ≤ 1.5/mg/dL
9. No active CNS metastatic disease at screening.

   * Patients with a history of CNS melanoma lesions must have had lesions resected by surgery and/or gamma knife irradiation at least 3 months prior to study entry.
   * The total number of CNS lesions at diagnosis should not have exceeded 3.
10. Written informed consent

Exclusion Criteria:

1. Patients who have received \> 8 cycles of cytotoxic chemotherapy or metastatic melanoma
2. Patients who have received any chemotherapy \< 4 weeks before the beginning of the trial
3. Patients who have received interferon alpha (IFNα-2b) or sargramostim (GM-CSF) \< 4 weeks before the beginning of the trial
4. Patients who have received high-dose interleukin-2 (IL-2) \< 4 weeks before the beginning of the trial
5. Patients that have been diagnosed with more than 3 CNS melanoma lesions.
6. Patients that have been diagnosed with more than 5 hepatic metastases or any hepatic metastasis \> 5 cm.
7. Baseline serum LDH \> 1.1 times the upper limit of normal
8. Patients who are HIV+ (HIV patients are often profoundly immunodeficient because of the viral infection and this additional parameter will interfere with the evaluation of DC induced immune responses in melanoma patients. Furthermore, the safety of collecting DCs, loading them with antigen and re-infusing these cells to HIV+ patients has not yet been determined.)
9. Pregnancy (Pregnancy is associated with considerable immunosuppression 70 and this additional parameter will interfere with the evaluation of DC induced immune responses in melanoma patients. In addition, the safety and tolerability of cell body-loaded DC given subcutaneously is entirely unknown.)
10. Patients who have received corticosteroids or other immunosuppressive agents \< 4 weeks before beginning the trial
11. Patients with active asthma and/or on treatment for asthma
12. Patients with angina pectoris
13. Patients with congestive heart failure
14. Patients with a history of autoimmune disease including lupus erythematosus, rheumatoid arthritis or thyroiditis
15. Patients with active infections including viral hepatitis
16. Patients with a history of neoplastic disease other than melanoma \< 5 years prior to entry on the trial except for patients with carcinomas in situ of the cervix and basal/squamous cell carcinomas of the skin. Patients who have any of these two types of cancer and melanoma can be included.

Primary outcomes:
measure: Induction of melanoma-specific CD8+T Cell Immunity.
timeFrame: 2 years
Secondary outcomes:
measure: Rate of objective clinical responses.
timeFrame: 2 years
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Baylor University Medical Center
state: Texas
Study officials:
affiliation: Baylor Institute for Immunology Research: Baylor University Medical Center
name: Joseph Fay, M.D.
role: PRINCIPAL_INVESTIGATOR
References: